Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMRXNASDAQ:CRNXNASDAQ:MRUSNASDAQ:SRRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMRXChimerix$8.54$8.51$0.75▼$8.55$801.09M-0.172.37 million shsN/ACRNXCrinetics Pharmaceuticals$30.68-6.2%$31.96$24.10▼$62.53$2.87B0.31861,138 shs1.14 million shsMRUSMerus$41.32-3.4%$43.51$33.19▼$61.61$2.86B0.94719,048 shs556,197 shsSRRKScholar Rock$30.85-0.5%$31.63$6.76▼$46.98$2.93B0.371.27 million shs846,155 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMRXChimerix0.00%0.00%+0.12%+102.85%+779.87%CRNXCrinetics Pharmaceuticals-6.33%-9.12%+10.92%-17.04%-39.71%MRUSMerus-3.39%-6.49%+4.45%+0.17%-12.25%SRRKScholar Rock-0.69%-6.26%+14.01%-22.78%+112.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMRXChimerix2.2469 of 5 stars1.04.00.04.10.02.50.6CRNXCrinetics Pharmaceuticals3.5555 of 5 stars3.51.00.03.72.72.50.0MRUSMerus3.2068 of 5 stars4.63.00.00.03.21.70.0SRRKScholar Rock3.9566 of 5 stars3.50.00.04.43.13.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMRXChimerix 2.00Hold$8.53-0.08% DownsideCRNXCrinetics Pharmaceuticals 2.92Moderate Buy$73.00137.94% UpsideMRUSMerus 3.13Buy$85.15106.08% UpsideSRRKScholar Rock 3.00Buy$42.6738.30% UpsideCurrent Analyst Ratings BreakdownLatest CMRX, CRNX, SRRK, and MRUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025MRUSMerusWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$91.00 ➝ $89.004/28/2025MRUSMerusWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/9/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$83.00 ➝ $83.003/28/2025MRUSMerusGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$109.00 ➝ $109.003/25/2025CRNXCrinetics PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.003/25/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.003/18/2025MRUSMerusGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$109.00 ➝ $109.003/17/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.003/10/2025MRUSMerusBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$73.00 ➝ $70.003/5/2025CMRXChimerixJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$10.00 ➝ $8.503/5/2025CMRXChimerixWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$7.00 ➝ $8.55(Data available from 5/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMRXChimerix$212K3,778.71N/AN/A$2.17 per share3.94CRNXCrinetics Pharmaceuticals$1.04M2,764.71N/AN/A$8.07 per share3.80MRUSMerus$36.13M79.11N/AN/A$6.17 per share6.70SRRKScholar Rock$33.19M88.17N/AN/A$3.12 per share9.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMRXChimerix-$82.10M-$0.99N/AN/AN/AN/A-50.78%-44.94%N/ACRNXCrinetics Pharmaceuticals-$214.53M-$3.71N/AN/AN/AN/A-36.12%-31.89%N/AMRUSMerus-$154.94M-$3.27N/AN/AN/A-680.61%-38.89%-31.16%5/14/2025 (Estimated)SRRKScholar Rock-$165.79M-$2.45N/AN/AN/AN/A-145.60%-91.83%5/14/2025 (Estimated)Latest CMRX, CRNX, SRRK, and MRUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MRUSMerus-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million5/14/2025Q1 2025SRRKScholar Rock-$0.63N/AN/AN/AN/AN/A5/8/2025Q1 2025CRNXCrinetics Pharmaceuticals-$0.99-$1.04-$0.05-$1.04$0.10 million$0.36 million3/21/2025Q4 2024CMRXChimerix-$0.26-$0.25+$0.01-$0.25$0.31 million$0.06 million2/27/2025Q4 2024CRNXCrinetics Pharmaceuticals-$0.92-$0.88+$0.04-$0.88$0.73 millionN/A2/27/2025Q4 2024MRUSMerus-$0.89-$0.41+$0.48-$0.41$10.57 million$9.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMRXChimerixN/AN/AN/AN/AN/ACRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMRXChimerixN/A6.336.33CRNXCrinetics PharmaceuticalsN/A16.3916.38MRUSMerusN/A8.328.32SRRKScholar Rock0.633.883.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMRXChimerix45.42%CRNXCrinetics Pharmaceuticals98.51%MRUSMerus96.14%SRRKScholar Rock91.08%Insider OwnershipCompanyInsider OwnershipCMRXChimerix13.10%CRNXCrinetics Pharmaceuticals4.60%MRUSMerus4.57%SRRKScholar Rock13.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMRXChimerix9093.80 million78.15 millionOptionableCRNXCrinetics Pharmaceuticals21093.63 million87.17 millionOptionableMRUSMerus3769.18 million65.34 millionOptionableSRRKScholar Rock14094.86 million75.64 millionOptionableCMRX, CRNX, SRRK, and MRUS HeadlinesRecent News About These CompaniesFairmount Funds Management LLC Takes $84.84 Million Position in Scholar Rock Holding Co. (NASDAQ:SRRK)May 10 at 8:04 AM | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Shares Sold by Corton Capital Inc.May 10 at 6:06 AM | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Shares Sold by Axa S.A.May 10 at 4:33 AM | marketbeat.comScholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025May 9 at 6:56 PM | seekingalpha.comHsbc Holdings PLC Invests $571,000 in Scholar Rock Holding Co. (NASDAQ:SRRK)May 9 at 3:56 AM | marketbeat.com21,055 Shares in Scholar Rock Holding Co. (NASDAQ:SRRK) Purchased by Blackstone Inc.May 8 at 6:21 AM | marketbeat.comBayesian Capital Management LP Takes $990,000 Position in Scholar Rock Holding Co. (NASDAQ:SRRK)May 8 at 5:20 AM | marketbeat.comBellevue Group AG Has $108.51 Million Stake in Scholar Rock Holding Co. (NASDAQ:SRRK)May 6, 2025 | marketbeat.comTudor Investment Corp ET AL Purchases 34,262 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)May 6, 2025 | marketbeat.comTower Research Capital LLC TRC Sells 10,041 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)May 6, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Receives $42.67 Consensus Target Price from BrokeragesMay 5, 2025 | americanbankingnews.comBoxer Capital Management LLC Purchases New Shares in Scholar Rock Holding Co. (NASDAQ:SRRK)May 4, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Given Average Recommendation of "Buy" by BrokeragesMay 4, 2025 | marketbeat.comRA Capital Management L.P. Purchases New Position in Scholar Rock Holding Co. (NASDAQ:SRRK)May 3, 2025 | marketbeat.comChutes & Ladders—Scholar Rock rocks the boat with new execsMay 2, 2025 | fiercebiotech.comMonashee Investment Management LLC Takes Position in Scholar Rock Holding Co. (NASDAQ:SRRK)May 2, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Stake Decreased by Samsara BioCapital LLCMay 2, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Holdings Raised by Voya Investment Management LLCMay 2, 2025 | marketbeat.comCANADA LIFE ASSURANCE Co Grows Stake in Scholar Rock Holding Co. (NASDAQ:SRRK)May 2, 2025 | marketbeat.comRaymond James Financial Inc. Purchases New Shares in Scholar Rock Holding Co. (NASDAQ:SRRK)May 2, 2025 | marketbeat.comScholar Rock (SRRK) Expected to Announce Earnings on TuesdayMay 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCMRX, CRNX, SRRK, and MRUS Company DescriptionsChimerix NASDAQ:CMRX$8.54 0.00 (0.00%) As of 04/21/2025Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.Crinetics Pharmaceuticals NASDAQ:CRNX$30.68 -2.02 (-6.18%) As of 05/9/2025 04:00 PM EasternCrinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Merus NASDAQ:MRUS$41.32 -1.45 (-3.39%) As of 05/9/2025 03:51 PM EasternMerus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Scholar Rock NASDAQ:SRRK$30.85 -0.14 (-0.45%) As of 05/9/2025 03:52 PM EasternScholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend Here's The Reason Goldman Sachs Is Bullish On MercadoLibre Stock GlobalFoundries Stock Hits Bottom: Is a Rebound Coming? What the ExtraHop Deal Means for CrowdStrike DoorDash’s Uptrend Is Gaining Momentum in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
